Melanotan II Side Effects: What the Research Shows (2026)

Overview

Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that was originally developed at the University of Arizona for potential use as a sunless tanning agent and later investigated for sexual dysfunction. Despite never receiving FDA approval for any indication, Melanotan II has become widely available through unregulated online sources and is used for tanning, appetite suppression, and sexual enhancement. This article provides a comprehensive review of documented and reported side effects. It is critical to emphasize that Melanotan II is not approved by any major regulatory agency, is classified as a banned substance in Australia, the UK, and several European countries, and carries significant safety concerns — particularly related to dermatologic changes that may complicate melanoma screening. This guide is strictly educational and does not constitute medical advice or endorsement of Melanotan II use.

Common Side Effects: What Most Users Experience

Nausea is the most frequently reported side effect of Melanotan II, occurring in a large majority of users — early clinical research reported nausea in up to 85% of participants following subcutaneous injection. The nausea typically occurs within 15-60 minutes of injection, lasts 30 minutes to several hours, and is dose-dependent. Many users report that nausea severity decreases with continued use as tolerance develops, and some mitigate it by injecting before bedtime so that the nausea period passes during sleep. Facial flushing is the second most common acute effect, resulting from Melanotan II's vasodilatory properties through melanocortin receptor activation. Flushing typically presents as redness and warmth in the face and sometimes the upper chest, beginning within minutes of injection and lasting 30-90 minutes. This effect is generally considered benign but can be uncomfortable. Appetite suppression is a well-documented effect of melanocortin receptor agonists. The melanocortin-4 receptor (MC4R) plays a central role in appetite regulation and energy homeostasis in the hypothalamus, and Melanotan II activates this receptor in addition to the MC1R receptor responsible for pigmentation effects. Some users report significant reduction in hunger and food intake, which has led to off-label use specifically for appetite control — a concerning practice given the compound's unregulated status and the availability of FDA-approved alternatives for weight management. Fatigue and lethargy are commonly reported in the initial days of use, with most users describing a sensation of drowsiness or low energy for several hours following injection. This typically diminishes with repeated administration. Injection site reactions — redness, soreness, and small lumps at the subcutaneous injection site — are consistent with subcutaneous administration of any peptide compound and are not specific to Melanotan II.

• Nausea: Reported in up to 85% of users in early research; dose-dependent; typically occurs within 15-60 minutes of injection and lasts 30 minutes to several hours
• Facial flushing: Redness and warmth in the face lasting 30-90 minutes post-injection; caused by melanocortin receptor-mediated vasodilation
• Appetite suppression: Significant reduction in hunger via MC4R activation; persists throughout the dosing period
• Fatigue and drowsiness: Common in the first several days of use; typically improves with continued administration
• Injection site reactions: Redness, soreness, and occasional lumps at the injection site; consistent with subcutaneous peptide injection generally
• Mild headache: Reported by some users, particularly with initial doses; may be related to vasodilatory effects

Dermatologic Concerns: Mole Changes and Melanoma Risk

The most significant safety concern surrounding Melanotan II relates to its dermatologic effects — specifically, the darkening, enlargement, and increased irregularity of existing moles and nevi, and the potential development of new pigmented lesions. These effects are not merely cosmetic; they have direct implications for melanoma detection and dermatologic monitoring. Melanotan II stimulates melanocyte activity through MC1R activation, which increases eumelanin production and causes skin darkening. However, melanocytes in moles and nevi respond to this stimulation disproportionately, resulting in visible changes to these lesions. Multiple case reports in the dermatologic literature have documented new atypical nevi, dysplastic nevi, and changes in existing moles in Melanotan II users. A 2015 case series published in the British Journal of Dermatology documented multiple cases of eruptive nevi (sudden appearance of new moles) following Melanotan II use. A 2017 review in the Australasian Journal of Dermatology examined several cases of melanoma diagnosed in Melanotan II users and raised the critical concern that MT-II-induced changes to moles may mask or mimic early melanoma, complicating dermoscopic assessment and potentially delaying diagnosis. The mechanism of concern is straightforward: the ABCDE criteria used for melanoma screening (Asymmetry, Border irregularity, Color variation, Diameter, and Evolution) rely on detecting changes in moles over time. Melanotan II causes exactly these types of changes — darkening, enlargement, and altered borders — in benign moles. This means that a clinician performing a skin check on a Melanotan II user may have difficulty distinguishing between benign MT-II-induced mole changes and early-stage melanoma without performing biopsies. The concern is not only that Melanotan II might directly cause melanoma (which has not been proven but also cannot be ruled out, given its stimulation of melanocyte proliferation and activity), but that it creates a background of mole changes that makes melanoma harder to detect even if it arises from unrelated causes such as UV exposure.

• Darkening of existing moles and nevi is nearly universal with Melanotan II use and is dose-dependent
• New moles (eruptive nevi) have been documented in multiple case reports following MT-II use
• Dysplastic (atypical) nevi changes have been reported — these are considered melanoma precursors in some classification systems
• MT-II-induced mole changes mimic the ABCDE criteria used for melanoma screening, potentially masking early-stage melanoma
• Several melanoma cases have been reported in MT-II users, though a direct causal link has not been established
• All current and former MT-II users should undergo comprehensive dermatologic examination with dermoscopy and establish baseline mole mapping

Cardiovascular and Blood Pressure Effects

Melanotan II's effects on the cardiovascular system are documented but incompletely characterized due to the absence of large-scale safety trials. Melanocortin receptors are expressed in cardiovascular tissues, and activation of these receptors can influence blood pressure, heart rate, and vascular tone. In the limited clinical research that has been conducted, Melanotan II produced transient increases in blood pressure in some participants, typically occurring within the first hour after injection and resolving within several hours. The magnitude of blood pressure elevation reported in early clinical studies was generally modest — systolic increases of 5-15 mmHg — but this was observed in healthy young volunteers. The effect in individuals with pre-existing hypertension, cardiovascular disease, or those taking antihypertensive medications is unknown because these populations were excluded from early studies. Some users report palpitations (awareness of heartbeat) and transient tachycardia (increased heart rate) following injection. These effects are likely related to the compound's vasodilatory and sympathetic nervous system interactions. While these cardiovascular effects may be clinically insignificant in healthy young adults, they represent a genuine concern for individuals with cardiovascular risk factors. The combination of Melanotan II with phosphodiesterase-5 inhibitors (such as sildenafil or tadalafil), which is reportedly common among users seeking sexual enhancement effects, raises additional cardiovascular concerns because both compound classes affect blood pressure through different mechanisms, and their combined effect on blood pressure has not been studied. Individuals with any form of cardiovascular disease, hypertension, or those taking cardiovascular medications should not use Melanotan II, and anyone experiencing chest pain, severe headache, or sustained blood pressure changes after injection should seek immediate medical evaluation.

• Transient blood pressure increases (5-15 mmHg systolic) reported in early clinical research; occurs within 1 hour of injection
• Palpitations and mild tachycardia reported by some users following injection
• Cardiovascular effects in patients with pre-existing heart disease or hypertension are unknown — these populations were excluded from studies
• Combination with PDE-5 inhibitors (sildenafil, tadalafil) may compound blood pressure effects — this interaction has not been studied
• Anyone with cardiovascular disease, hypertension, or on cardiac medications should avoid Melanotan II

Sexual Side Effects: Spontaneous Erections and Libido Changes

Melanotan II is a non-selective melanocortin receptor agonist, and among the receptors it activates is MC4R, which is involved in sexual arousal and erectile function. In fact, Melanotan II's sexual effects led to the development of bremelanotide (PT-141/Vyleesi), a related compound that was refined for greater selectivity and eventually received FDA approval for hypoactive sexual desire disorder in premenopausal women. The sexual effects of Melanotan II are among its most notable and, depending on context, either desired or problematic. In men, spontaneous penile erections are a well-documented effect, occurring in a significant percentage of users — early clinical research reported erections in up to 33% of male participants. These erections can occur without sexual stimulation, may be prolonged, and in rare cases have been associated with priapism (prolonged painful erection lasting more than 4 hours), which constitutes a medical emergency requiring immediate treatment. The risk of priapism, while rare, is a genuine safety concern, particularly when Melanotan II is combined with PDE-5 inhibitors or other erectile dysfunction treatments. In women, Melanotan II has been associated with increased sexual arousal and genital sensitivity. The limited clinical data that exists, primarily from the bremelanotide development program, suggests that melanocortin agonists can increase desire and arousal in women, though the broader safety implications specific to MT-II (as opposed to the refined bremelanotide molecule) are less well-characterized. Beyond the acute effects, some users report sustained increases in libido throughout the period of Melanotan II use, which normalizes after discontinuation. While increased sexual desire is considered a benefit by some users, uncontrolled sexual side effects can be distressing, socially inappropriate, and potentially dangerous in the case of priapism. The sexual effects underscore that Melanotan II is a biologically active compound with systemic effects beyond skin pigmentation, and its non-selective receptor binding means that users cannot isolate the tanning effect from other melanocortin-mediated responses.

• Spontaneous erections reported in up to 33% of male users in clinical research; can occur without sexual stimulation
• Priapism (prolonged erection >4 hours) has been reported rarely — this is a medical emergency requiring immediate treatment
• Increased libido and sexual arousal documented in both men and women
• Sexual effects are mediated by MC4R activation — the same mechanism targeted by FDA-approved bremelanotide (Vyleesi)
• Combination with PDE-5 inhibitors increases priapism risk — concurrent use is strongly discouraged
• Sexual effects normalize after discontinuation of Melanotan II

Regulatory Status and Safety Warnings

Melanotan II has never been approved by the FDA, the European Medicines Agency (EMA), the Therapeutic Goods Administration (TGA) in Australia, or any other major regulatory body for any therapeutic indication. The compound exists in a regulatory gray area in some jurisdictions and is outright banned in others. Australia's TGA has issued multiple public warnings about Melanotan II, classifying it as a prescription-only medicine that has never been evaluated for safety, quality, or efficacy through the regulatory approval process. The TGA has specifically warned about the risks of melanoma promotion, cardiovascular effects, and contamination risks from unregulated products. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has similarly warned against Melanotan II use and has conducted enforcement actions against suppliers. Several European countries have issued comparable warnings through their national regulatory agencies. In the United States, Melanotan II is not scheduled as a controlled substance, but it is not legal to sell for human consumption — it can only be sold labeled as a research chemical "not for human use." This labeling technicality allows vendors to sell the compound while technically complying with regulations, though the practical reality is that nearly all purchases are for self-administration. The lack of regulatory oversight means there is no quality control, standardized dosing, batch testing, or adverse event reporting system for Melanotan II. Products purchased from unregulated sources may contain incorrect peptide content, impurities, bacterial contamination, or entirely different compounds than advertised. Third-party testing of commercially available Melanotan II products has revealed significant variability in actual peptide content and purity. The regulatory consensus across multiple countries is clear: Melanotan II has not demonstrated an acceptable safety profile for human use, and its risk-benefit ratio is unfavorable given the availability of safer alternatives for tanning (sunscreen and gradual UV exposure) and sexual dysfunction (FDA-approved treatments with established safety profiles).

• Not approved by FDA, EMA, TGA, or any major regulatory body for any indication
• Banned or restricted in Australia, United Kingdom, and several European countries
• Classified as a prescription-only medicine in Australia despite having no approved prescription use
• Multiple regulatory agencies have issued public safety warnings specifically about Melanotan II
• Sold in the US only as "research chemical not for human consumption" — a legal technicality
• No quality control, standardized dosing, or adverse event reporting exists for commercially available products
• Third-party testing has revealed significant variability in purity and content of commercially available MT-II

References

1. Eruptive nevi associated with Melanotan II use: a case series (2015) — PubMed
2. Melanoma and Melanotan: a case report and review of the literature (2017) — PubMed
3. Subcutaneous administration of Melanotan II: clinical studies in human volunteers (1999) — PubMed
4. The melanocortin system and melanoma risk: melanocortin-1 receptor variants (2014) — PubMed
5. Melanotan II: an internet-driven, unregulated drug with potential for melanoma risk (2014) — PubMed